Janssen Collaborates with Idorsia on Aprocitentan
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 12 (Table of Contents)
Published: 20 Dec-2017
DOI: 10.3833/pdr.v2017.i12.2291 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Agreeing to significant financial terms, Janssen Biotech has exercised its option to collaborate with Idorsia Pharmaceuticals to co-develop and commercialise aprocitentan in return for a one-time milestone payment of US$230 M and extremely high royalty rates upon commercialisation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS